Literature DB >> 32242389

Danggui Buxue Tang ameliorates bleomycin-induced pulmonary fibrosis in rats through inhibiting transforming growth factor-β1/Smad3/ plasminogen activator inhibitor-1 signaling pathway.

Jiepeng Wang1, Chaoyi Fang1,2, Shaoxian Wang1, Fang Fang1,2, Xinqiao Chu1, Na Liu1, Chenxi Lu1, Shuo Wang1, Wei Li1.   

Abstract

OBJECTIVE: To investigate the effect of Danggui Buxue Tang (DBT), a decoction from Traditional Chinese Medicine, on bleomycin-induced pulmonary fibrosis in rats, and to propose the possible underlying mechanism.
METHODS: Forty male Sprague-Dawley rats were randomly divided into sham group, model group, prednisone group and DBT group. Pulmonary fibrosis rat model was established by intratracheal injection with bleomycin. Body weight and lung index were monitored. Histopathologic examination and collagen deposition were determined using Hematoxylin and eosin (HE) and Masson's trichrome staining. Immunohistochemistry staining was applied to observe the expression of alpha-smooth muscle actin (α-SMA). mRNA expression of α-SMA, collagen Ⅰ and collagen Ⅲ were measured by real-time fluorescence quantitative PCR (RT-qPCR). Inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and IL-1β in serum were detected by Enzyme-linked immunosorbent assay. Alkali hydrolysis method was conducted to investigate the content of hydroxyproline (HYP). Transforming growth factor-β1 (TGF-β1), Smad3 and plasminogen activator inhibitor-1 (PAI-1) protein level were examined by Western blot assay.
RESULTS: DBT significantly reduced the severity of bleomycin-induced pulmonary fibrosis and inflammation as indicated by minimizing the lost of weight, and by lowering the levels of lung index, inflammation score, Ashcroft score, collagen volume fraction (%), HYP, α-SMA, collagen Ⅰ, collagen Ⅲ, TNF-α, IL-6, IL-1β, TGF-β1, Smad3 and PAI-1, consistent with the effect of prednisone.
CONCLUSION: Our findings suggest that DBT is able to ameliorate the pulmonary fibrosis, the possible mechanism may involve inhibition of pulmonary inflammation and collagen deposition, possibly via suppressing TGF-β1/Smad3/PAI-1 signaling pathway.

Entities:  

Keywords:  Danggui Buxue Tang; Plasminogen inactivator; Pulmonary fibrosi; Smad3 protein; Transforming growth factor beta 1

Year:  2020        PMID: 32242389

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  7 in total

Review 1.  The Latest Research Advances of Danggui Buxue Tang as an Effective Prescription for Various Diseases: A Comprehensive Review.

Authors:  Chen-Chen Ma; Yue-Hua Jiang; Yan Wang; Rui-Rong Xu
Journal:  Curr Med Sci       Date:  2022-10-17

2.  Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats.

Authors:  Quanyu Du; Xuanyu Wu; Liping An; Rui Zhou; Xiang Xiao; Cheng Wu; Fei Wang; Han Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-13       Impact factor: 2.650

3.  Assessment of Alamandine in Pulmonary Fibrosis and Respiratory Mechanics in Rodents.

Authors:  Renata Streck Fernandes; Henrique Bregolin Dias; Wynnie Amaral de Souza Jaques; Tiago Becker; Katya Rigatto
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-05-18       Impact factor: 1.636

4.  Danggui Buxue Decoction Ameliorates Inflammatory Bowel Disease by Improving Inflammation and Rebuilding Intestinal Mucosal Barrier.

Authors:  Chengyin Li; Fenglin Zhu; Shasha Wang; Jing Wang; Bin Wu
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-19       Impact factor: 2.629

5.  Clinical efficacy of Chinese herbs for supplementing qi and activating blood circulation combined with N-acetylcysteine in the treatment of idiopathic pulmonary fibrosis: A systematic review and network meta-analysis.

Authors:  Qinglu Pang; Guodong Li; Fang Cao; Haoge Liu; Wan Wei; Yang Jiao
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

6.  Danggui Buxue Decoction Ameliorates Idiopathic Pulmonary Fibrosis through MicroRNA and Messenger RNA Regulatory Network.

Authors:  Huizhe Zhang; Xue Wang; Yanchen Shi; Mengying Liu; Qingqing Xia; Weilong Jiang; Yufeng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-26       Impact factor: 2.650

7.  Danggui Buxue Tang Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing the TLR4/NLRP3 Signaling Pathway in Rats.

Authors:  Jiepeng Wang; Hao Wang; Fang Fang; Chaoyi Fang; Shaoxian Wang; Chenxi Lu; Na Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-23       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.